Infigratinib (BGJ398)
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for Infigratinib (BGJ398), covering 2025-06-10 to 2025-06-10. Get the full timeline:
Most recent: Clinical Trial Update: Infigratinib for the Treatment of Advanced or Metastatic Solid Tumors in Patients With FGFR Gene Mutations [Phase 2]